Abstract
• ‘Big data’ provide challenges and opportunities for pharmaceutical R&D. • Currently available compound activity data and target annotations have ‘big data’ character. • Achieving compound data completeness is an elusive goal. • Extraction of knowledge from ‘big compound data’ is a must and does not depend on data completeness.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
